To analyze the clinical significance of BAMBI, authors studied its expression in CRC using immunohistochemical staining. They show that BAMBI overexpression is correlated with aggressive tumor phenotypes and predicts tumor recurrence and cancer-related death in CRC. BAMBI may be usable as a target for diagnostic and antibody medicine.

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

A new study indicates that African Americans with a family history of colorectal cancer are less likely to be screened than African Americans at average risk for the disease. There is also some evidence to indicate that AA with a family history are less likely to be screened than their white counterparts. The study is published in the July 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

Among patients with advanced colon cancer receiving treatment that includes chemotherapy, a family history of colorectal cancer is associated with a significant reduction in cancer recurrence and death, with the risk reduced further by having an increasing number of affected first-degree relatives, according to a study in the June 4 issue of JAMA.

Patient interventions are necessary to achieve higher rates of colorectal cancer screening in low-income and minority patients, according to two studies in the current issue of Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

Case Western Reserve University School of Medicine researchers published a study in the March 7th issue of The American Journal of Human Genetics identifying the hereditary components of colorectal cancer (CRC.)

New consensus colorectal cancer guidelines released today state for the first time that the primary goal of colorectal cancer screening is cancer prevention. Previous guidelines have given equal weight to tests for detecting cancer and preventing cancer. By removing polyps from the large bowel, colonoscopy is the only screening test that also prevents colorectal cancer.

A new study shows that health care providers play a key role in the likelihood their patients are screened for colorectal cancer.

A new study finds significant underuse of colorectal cancer screening procedures among Medicare beneficiaries. The study, published in the January 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, show that only 25 percent of Medicare patients received recommended screening during the study period.

New research presented at the 72nd Annual Scientific Meeting of the American College of Gastroenterology emphasizes the importance of colorectal cancer (CRC) screening among racial and ethnic minorities, who have a higher incidence of colorectal cancer compared to Caucasians.

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.

Two studies in the October issue of the journal Gastroenterology may help in refining recommendations for the use of colonoscopy to screen for colorectal cancer.